Detailed explanation of medical insurance coverage and medication of Eltrombopag/Eltrombopag

With the continuous improvement of the national medical insurance policy, as of March 2024, the original research drug Eltrombopag has been successfully included in the reimbursement scope of Class B medical insurance. This means that patients who meet specific indications will be able to enjoy reimbursement from the national medical insurance, thereby reducing the financial burden. However, patients who do not meet the conditions for medical insurance reimbursement still need to purchase this drug at their own expense, and its price is relatively high, which may bring certain financial pressure to the patient.

Eltrombopag is a drug with significant efficacy. Its main uses after its launch include increasing platelet count, treating immune thrombocytopenia (ITP) and aplastic anemia. Its mechanism of action is by simulating the function of a hormone called "thrombopoietin" in the body, binding to specific receptors in the bone marrow, thereby stimulating the production of platelets. This mode of action helps improve patients' platelet counts, thereby alleviating related symptoms.

Eltrombopag is available on the market in tablet and powder form, which can be made into a suspension for oral use. It should be noted that this drug is a prescription drug and must be used under the guidance of a doctor. Regarding the dosage of eltrombopag, it will be adjusted based on the age of the patient and the specific disease being treated. The goal is to maintain appropriate platelet levels to ensure patient health and safety.

However, you need to be alert to possible side effects when using eltrombopag. Particularly when combined with interferon and ribavirin in the treatment of chronic hepatitis C, the risk of hepatotoxicity may be increased. In addition, there are reports that the drug may cause skin-related adverse reactions, such as hyperpigmentation and yellowing of the skin.